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Relationship between device
acceptance and patient-reported
outcomes in Left Ventricular Assist
Device (LVAD) recipients
Crispino Tosto1, Luigi Adamo2, Heidi Craddock2, Maria Di Blasi1, Rosario Girgenti3,
Francesco Clemenza3, Robert M. Carney4 & Gregory Ewald2
The number of Left Ventricular Assist Devices (LVADs) implanted each year is rising. Nevertheless, there
are minimal data on device acceptance after LVAD implant, and on its relationship with patient-reported
outcomes. We designed a cross-sectional study to address this knowledge gap and test the hypothesis
that low device acceptance is associated with poorer quality of life, depression and anxiety. Self-report
questionnaires were administered to assess quality of life (12-item Kansas City Cardiomyopathy
Questionnaire quality of life subscale), level of anxiety (7-item Generalized Anxiety Disorder; GAD7), level of depression (9-item Patient Health Questionnaire; PHQ-9) and device acceptance (Florida
Patient Acceptance Survey; FPAS) to 101 consecutive patients presenting to LVAD clinic. Regression
analysis showed a strong correlation between device acceptance and both psychological distress
(p < 0.001) and quality of life (p < 0.001). Analysis of the sub-scales of the FPAS showed that patients
had significant body image concerns, but return to function and device-related distress were the main
drivers of the observed correlation between device acceptance and patient well-being. Younger age
was associated with lower device acceptance (r = 0.36, p < 0.001) and lower quality of life (r = 0.54,
p < 0.001). These findings suggest that interventions targeting device acceptance should be explored to
improve outcomes in LVAD recipients.
The few small studies that have investigated the impact of LVAD therapy on psychological distress1 have generally
found that LVAD recipients experience symptoms of depression and anxiety immediately after implant2, but their
psychological distress diminishes over time3–6. However, one study reported that moderate symptoms of anxiety
and depression may remain at least six months after the implant in spite of improved indices of quality of life
(QoL)7. Clearly, this question needs further study.
There is also very little data on patients’ acceptance of the implanted device, and all of the information available comes from very small studies (<30 patients). Most have found that patients appear to be satisfied with the
LVAD and tend to accept it as an essential component of their own bodies and lives8–10. However, one study found
that LVAD recipients positively evaluated their experience with the device immediately after surgery but tended
to be less satisfied with the device as time from the implant increased due to worsening in physical functioning11.
There is also minimal information about the impact that the LVAD, which is partially visible, has on patients’
perception of their body image10,12. Chapman et al. studied 6 patients who reported that LVAD implant was an
upsetting event, due to sudden and significant body changes caused by the device12. In a sample of 9 patients,
Marcuccilli et al. found that even when patients came to terms with the modifications that the presence of the
LVAD had on their own body, they continued to worry about appearing “normal” in public10.
In summary, despite the rapidly growing number of LVAD implants, there are limited and contradictory data
about patients’ device acceptance, and no data about the relationship between patients’ device acceptance and the
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psychological well-being and QoL of LVAD recipients. Moreover, more needs to be known about the impact that
partially externalized LVADs have on body-image perception.
We hypothesized that worse levels of device acceptance, especially with regard to body-image, would be associated with poorer QoL and higher levels of depression/anxiety, and could therefore be identified as potential
therapeutic targets to improve outcomes post LVAD. To test this hypothesis, we designed a cross-sectional observational cohort study of consecutive patients presenting to the outpatient LVAD clinic of Barnes Jewish Hospital.

Materials and Method

Study population and design. Between July 2016 and December 2016, questionnaires were administered
to patients presenting for outpatient follow-up to assess QoL, levels of anxiety and depression, and device acceptance. All patients who were older than 18, had no cognitive impairment and were clinically stable were administered the questionnaires. The instruments were not administered at subsequent visits. Data were collected on a
cohort of 101 consecutive patients meeting study criteria. All patients provided informed consent, the study was
reviewed and approved by the Washington University Institutional Review Board and all data was collected in
accordance with relevant guidelines and regulations.
Measures. Symptoms of depression. The 9-item Patient Health Questionnaire was used to assess patients’
symptoms of depression. Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. The PHQ-9 has been shown to have acceptable validity and reliability in individuals with heart failure13. In
this study, a Cronbach’s alpha coefficient of 0.86 was found.
Symptoms of anxiety. Symptoms of anxiety were evaluated using the 7-item Generalized Anxiety Disorder
(GAD-7), with potential scores ranging from 0 to 21, with higher scores indicating more severe symptoms of
anxiety. The instrument has been shown to be a valid and reliable measure of anxiety14. In this study, a Cronbach’s
alpha coefficient of 0.90 was found.
Quality of life. Quality of life was measured using the 12-item Kansas City Cardiomyopathy Questionnaire
QoL subscale. The 12-item KCCQ provides an overall summary score as well as scores for the subscales Physical
Limitation, Symptom Frequency, QoL, and Social Limitation15. Given the potential overlap between the Physical
and Social Limitation subscales of the KCCQ-12 and the Return to Function subscale of the FPAS, we used only
the scores from the QoL subscale and considered them as a measure of participants’ global satisfaction with their
lives. In this study, a Cronbach’s alpha coefficient of 0.71 for the QoL subscale score was found.
Device acceptance. The Florida Patient Acceptance Survey (FPAS) was used to evaluate participants’ acceptance
of the LVAD. The FPAS is a self-report questionnaire that was originally developed to measure patients’ acceptance of implantable cardiac devices (i.e., pacemakers, implantable cardioverter defibrillators). It consists of 18
items scored on a 5-point Likert scale. A total score and separate scores for four subscales (Return to Function,
Positive Appraisal, Device-Related Distress, and Body Image Concerns) can be determined16. The Return to
Function subscale assesses the extent to which a patient has returned to adequately engage in occupational, social,
and physical activities. The Device-related Distress subscale evaluates the psychological distress associated with
the device, and the Positive Appraisal subscale refers to the benefits of having the device implanted. Finally, the
Body Image Concern subscale refers to perceived body disfigurement and feelings of being attractive. Validity
and internal consistency for both total scores and all subscales, have been established in individuals with heart
failure and implantable cardiac devices, and the FPAS has been shown to have robust performance independently
of the time since implant16–18. In this study, Cronbach’s alphas were found to be 0.78 for total scores and 0.58, 0.76,
0.74, and 0.72 for Return to Function, Positive Appraisal, Device-related Distress, and Body Image Concerns
respectively.
Socio-demographic and clinical variables. Socio-demographic data were obtained from a structured questionnaire. Clinical data were obtained from medical records.

Statistical analysis. We performed mean and modal imputations to substitute missing values (<3%) in the

continuous and categorical variables respectively. The bivariate associations between patients’ acceptance of the
LVAD (total scores and subscale scores), age, time since LVAD implant, and symptoms of depression, anxiety,
and QoL were assessed using Pearson’s correlation. The statistical significance of the difference between the FPAS
values recorded in our cohort and those reported in the literature was assessed using unpaired t-tests.
Linear regression models were used to investigate further the cross-sectional association between patients’
LVAD acceptance dimensions and the symptoms of depression, anxiety, and QoL. Patients’ age and time since
LVAD implant were a priori selected as potential confounding variables based on prior literature8,11,18,19, and
were added to regression models. To account for the possible confounding effect of the patients’ physical ability,
dummy variables for NYHA functional classes I and III were derived (with NYHA class II as the reference category) and entered as predictor variables. Unpaired t-tests were computed with Graph-Pad prism vs 7.01. All other
analyses were done using SPSS version 20. A p < 0.05 was considered significant. All data can be made available
upon request.

Results

Table 1 presents the characteristics of the 101 consecutive patients recruited for the study. The sample was primarily Caucasian (73.3%) and male (78.2%), with a mean age of 57.65. Most of the participants were in NYHA
functional class II (61.4%), and the average time from the diagnosis of heart failure was 9.78 years. Sixty-five %
of the patients originally received the device as a Destination Therapy (DT).Older patients were more likely to be
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Variables

Mean (SD) or N (%)

Range

Age

57.65 (14.18)

22–84

Sex
Male

79 (78.2)

Ethnicity
Caucasian

74 (73.3)

Black/African American

22 (21.8)

Asian/pacific islander

2 (2.0)

Another race/multiracial

3 (3.0)

Marital Status
Married or living with a partner

75 (74.2)

Separated or divorced

14 (13.9)

Widowed

2 (2.0)

Single/never married

10 (9.9)

Education
Less than high school

7 (6.9)

High school graduate

31 (30.7)

Some college

37 (36.6)

College graduate

19 (18.9)

Any post-graduate

7 (7.0)

Occupational status
Employed

8 (8.0)

Unemployed

7 (6.9)

Retired

45 (44.6)

On disability

40 (39.6)

Student

1 (1.0)

Perceived income adequacy
Totally inadequate

10 (9.9)

Not very well

29 (28.7)

Adequate

52 (51.5)

Very well

10 (9.9)

HF etiology
Ischemic

45 (55.4)

NYHA functional class
I

15 (14.9)

II

62 (61.4)

III

23 (22.8)

IV

1 (1.0)

Years since HF diagnosis

9.78 (8.12)

.30–35

LVAD Strategy
Destination therapy

66 (65.3)

Bridge to transplantation

35 (34.7)

Type of LVAD
HVAD

17 (16.8)

HeartMate II

73 (72.3)

HeartMate III

11 (10.9)

Months since LVAD Implant

19.48 (15.37)

2–69

Table 1. Socio-demographic and Clinical Characteristics of the Sample (N = 101) HF, heart failure; LVAD, Left
Ventricular Assist Device; NYHA, New York Heart Association.

implanted as DT. In fact while only half of the patients in each of the two lowest age tertiles (age 22–54 and 55–65)
were implanted as DT, almost 100% of the patients in the highest age tertile (65 to 84) were implanted without
the future perspective of heart transplant. The average time since LVAD implant was 19.48 months (SD = 15.37).
Analysis of the psychosocial measures (Table 2) showed that the average total scores of both the PHQ-9 and
the GAD-7 were below the cut-off point of 10 for clinically significant symptoms of depression and anxiety20,21,
although a sizeable percentage of participants reported clinically significant depression (23.8%) and anxiety
(12.9%). Ten % of the patients reported having self-harm ideation at least several days during the prior two weeks.
No patient reported active suicidal ideation. The average score on the KCCQ QoL subscale was 56.38.
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Variables

Mean (SD) or %

Range

PHQ-9†

6.12 (5.62)

0–20

PHQ-9 ≥ 10

23.8%

Self-harm Ideation‡

9.9%

GAD-7†

3.67 (4.69)

GAD-7 ≥ 10

12.9%

KCCQ QoL§

56.38 (26.28)

0–100

Return to function

41.31 (21.88)

0–100

Device-related distress

37.93 (23.15)

0–100

Positive appraisal

78.53 (23.66)

0–100

Body image concerns

39.33 (29.92)

0–100

Total score

60.74 (16.18)

0–100

0–18

Florida Patient Acceptance Surveyǁ

Table 2. Descriptive Statistics of Psychosocial Measures (N = 101)* GAD-7, 7-items Generalized Anxiety
Disorder; KCCQ, Kansas City Cardiomyopathy Questionnaire; PHQ-9, 9-items Patient Health Questionnaire.
*For all the psycho-social measures, the scale (and subscales) ranges are reported. † PHQ-9 and GAD-7: higher
scores mean higher psychological distress. ‡Percentage of patients reporting self-harm ideation at least several
days during the last two weeks (item 9 of the Phq-9). §KCCQ QoL: higher scores mean better health-related
status. ǁFlorida Patient Acceptance Survey: for total score and for Return to function and Positive appraisal,
higher scores mean better functioning. For Device-related distress and Body image concerns higher scores
mean worse functioning.

Measures

1

1. Age

—

2

3

4

5

6

7

8

9

2. Months since LVAD implant 0.16

—

3. PHQ-9

−0.20*

0.03

4. GAD-7

−0.19

0.12

0.81***

—

5. KCCQ QoL

0.54***

−0.03

−0.57***

−0.47***

—

6. Return to function

0.27**

−0.03

−0.47***

−0.42***

0.52***

—

7. Device-related distress

−0.32**

0.07

0.48***

0.55***

−0.45***

−0.49***

—

8. Positive appraisal

0.14

−0.07

−0.09

−0.06

0.01

0.18

−0.03

—

9. Body image concerns

−0.22*

0.06

0.28**

0.27**

−0.26**

−0.39***

0.45***

−0.11

—

10. FPAS total scores

.36***

−0.08

−0.50***

−0.50***

0.47***

0.76***

−0.78***

0.50***

−0.65***

—

Table 3. Correlation between Covariates, Symptoms of Depression and Anxiety, Quality of Life, and
Acceptance of the LVAD FPAS, Florida Patient Acceptance Survey; GAD-7, 7-item Generalized Anxiety
Disorder; KCCQQoL, Kansas City Cardiomyopathy Questionnaire QoL; LVAD, Left Ventricular Assist Device;
PHQ-9, 9-item Patient Health Questionnaire. *p < 0.05 **p < 0.01 ***p < 0.001.

With regard to LVAD acceptance dimensions, patients’ average device acceptance was 60.74. Analysis of
the four subscales of the FPAS showed that the acceptance of the implanted device was driven by a significant
positive appraisal of the LVAD (mean “Positive Appraisal” subscale score 78.53) and that this balanced body
image concerns (“body image concerns” subscale score mean 39.33), and the perception that the LVAD restored
appropriate functional levels only in part (“return to function” subscale mean score 41.31). The average reported
device-related distress was 37.93.
Analysis of bivariate associations (Table 3) showed that overall LVAD acceptance and almost all its subscales
were associated with both the PHQ-9 and the GAD-7 total scores, as well as with the KCCQ QoL subscale scores.
Specifically, a higher acceptance of the LVAD (FPAS total score) was associated with lower symptoms of depression (r = −0.50, p < 0.001) and anxiety (r = −0.50, p < 0.001) and higher perceived QoL (r = 0.47, p < 0.001).
However, among the FPAS subscales, only the “Return to Function”, “Device-Related Distress” and “Body
image concerns” subscales were associated with lower symptoms of depression and anxiety, while the “Positive
Appraisal” subscale scores were not associated with mood or QoL. The results also showed a high correlation
between anxiety and depression (r = 0.81, p < 0.001). Regarding the covariates, increasing age was associated
with fewer symptoms of depression (r = −0.20, p < 0.05) and with higher perceived QoL (r = 0.54, p < 0.001). A
trend was also found for the association between increasing age and lower levels of anxiety (r = −0.19, p = 0.06).
Increasing age was also associated with higher overall acceptance of the LVAD as measured by the FPAS total
scores (r = 0.36, p < 0.001), and with lower body image concerns as measured by the “Body Image Concerns”
subscale of the FPAS (r = −0.22, p < 0.05). No significant association was found between months since LVAD
implant and any of the measured patient-reported outcomes.
To further investigate the relationship between device acceptance and depression, anxiety, and QoL we built
linear regression models and studied the relationship of the different components of the FPAS with the 3 variables
Scientific Reports |
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Depression

Anxiety

QoL

Predictors

β

β

β

Return to function

−0.30**

Device-related distress
Positive Appraisal

0.41***

−0.20*

0.32**

0.46***

−0.26*

−0.02

−0.01

Body Image Concerns

0.02

−0.02

−0.08

Total R2

0.30***

0.33***

0.33***

Corrected Total R2

0.27***

0.31***

0.30***

0.01

Table 4. Unadjusted Linear Regression Analyses of Symptoms of Depression, Symptoms of Anxiety, and
Quality of Life on Device Acceptance Dimensions R2, Variance; Corrected Total R2,Variance corrected for
the number of predictors; β, Standardized regression coefficient. QoL, Quality of Life. *p < 0.05 **p < 0.01
***p < 0.001.

Depression

Anxiety

QoL

Predictors

β

β

β

Return to function

−0.30**

Device-related distress
Positive appraisal

0.32**

−0.21*

0.36***

0.45***

−0.15
−0.13

−0.02

0.01

Body image concerns

0.01

−0.02

Total R2

0.30***

0.34***

0.49***

Corrected Total R2

0.26***

0.30***

0.45***

0.03

Table 5. Linear Regression Analyses Predicting Symptoms of Depression, Symptoms of Anxiety, and Quality
of Life from Device Acceptance Dimensions, Adjusted for Age and Time since LVAD Implant R2,variance;
Corrected Total R2,Variance corrected for the number of predictors; β, Standardized regression coefficient; QoL,
Quality of Life; LVAD, Left Ventricular Assist Device. *p < 0.05 **p < 0.01 ***p < 0.001.

(Table 4). This analysis confirmed the presence of a strong relationship between FPAS scores and depression
(R2 = 0.30, F (4, 96) = 10.27, p < 0.001), anxiety (R2 = 0.33, F(4, 96) = 12.02, p < 0.001) and QoL (R2 = 0.33, F(4,
96) = 11.62, p < 0.001) respectively. The relationship between the FPAS, anxiety, depression, and QoL was mainly
driven by a significant influence of the dimensions of “Return to function” and “Device-related distress”. The
dimension “Return to function” had the largest impact on QoL (β = 0.41, p < 0.001) and had a negative relationship with depression (β = −0.30, p < 0.01) and anxiety (β = −0.20, p < 0.05). The dimension “Device-related
distress” had the largest impact on anxiety (β = 0.46, p < 0.001) but was also associated with depression (β = 0.32,
p < 0.01) and QoL (β = −0.26, p < 0.05). The regression analysis did not confirm the relationship between the
“Body image concerns” subscale score and depression, anxiety or QoL (β between 0.01 and 0.08, not statistically
different from 0).
After accounting for the effects of age and time since LVAD implant, the only dimensions of the FPAS correlating with patients’ emotional distress and QoL were the “Return to function” and the “Device related distress”
dimensions (Table 5). A lower score on “Return to function” was associated with a higher level of depression
(β = −0.30, p < 0.01) and anxiety (β = −0.21, p < 0.05) and with lower QoL (β = 0.36, p < 0.001). The dimension
“Device-related distress” had a strong influence on both depression (β = 0.32, p < 0.05) and anxiety (β = 0.45,
p < 0.001). After adjusting for covariates, the relationship between “Device-related distress” and QoL was no
longer statistically significant (β = −0.15, p = 0.11).
As a further sensitivity analysis, we tested the effect of adding the NYHA functional class to the linear
regression models and confirmed that correcting for NYHA class did not significantly change our findings
(Supplementary Table 1).

Discussion

This is by far the largest study assessing body image concerns and device acceptance in LVAD recipients, and one
of the largest studies assessing psychological distress in a population of real-world continuous flow LVAD recipients. Age and gender distributions in our patient population were roughly comparable to those reported in the
most recent Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) and European
Registry for Patients with Mechanical Circulatory Support (EUROMACS) reports22,23. The study confirmed some
findings from prior smaller studies3–5 and produced some novel and, in some cases, unexpected findings.

Confirmation and Extension of Prior Work. First, we found that in the outpatient setting most patients

living with an LVAD had a perceived QoL comparable to that observed in heart failure patients living without an LVAD (56.38 ± 26.28 vs 54.4 ± 24.1)24. This finding is consistent with data collected in clinical trials on
LVAD25 and it supports the notions that: 1) LVAD support in the outpatient setting is characterized by better
patient-reported QoL than among hospitalized LVAD patients; 2) LVAD support is associated with lower QoL
than heart transplant26.
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Second, we found that increasing age correlates with higher perceived QoL. This is consistent with what was
previously observed in a retrospective analysis of the INTERMACS registry27.
Third, patients in our cohort reported a positive evaluation of the device as measured by the FPAS positive
appraisal subscale, although the mean positive appraisal score for the LVAD was slightly lower than that previously reported in ambulatory heart failure patients for ICDs (78.53 ± 23.66 in our study vs 90.3 ± 18.5 in ICD
recipients28, p < 0.01, Table 2). At the same time, patients reported significant device-related distress and body
image concerns, far greater than those reported from patients who received ICDs (“device related distress” subscale score 37.93 ± 23.15 in our study vs 15.6 ± 20.3 in ICD recipients28, p < 0.001; “body image concerns” subscale score 39.33 ± 29.92 in our study vs 10.6 ± 22.2 in ICD recipients28, p < 0.001). Such findings are consistent
with those reported in a smaller study in which LVAD recipients reported a positive global perception of their
LVAD in spite of several negative somatic and QoL consequences11. In this regard, it should be noted that most of
the participants in the present study were married or living with a partner. This may at least partially explain their
ability to develop a positive evaluation of the device in spite of relevant difficulties, given the widely recognized
supportive role played by partners in dealing with stressful conditions such as chronic illness29.
Fourth, we found clinically significant levels of depression and anxiety in 24% and 13% of patients respectively, with a small but non-negligible percentage of participants reporting at least occasional suicidal or self-harm
ideation. These percentages are comparable to those reported in previous smaller studies of LVAD recipients and
among individuals treated medically for heart failure6,7,30. It bears emphasis that while the existing literature on
very small cohorts suggests a significant decrease over time in symptoms of depression and anxiety2,3,6, we did not
find a significant association between time since LVAD implant and measures of psychosocial distress (Table 3).
Additionally, percentages of patients with clinically relevant symptoms of psychological distress found in the
current study are higher than those reported by research focusing on symptoms severity of anxiety and depression following a heart transplantation, where less than 8% and 6% of patients suffered from moderate to strong
symptoms of depression and anxiety respectively31,32.

Novel and Unexpected Findings. Our bivariate analysis showed a strong correlation between device
acceptance and both psychological distress and QoL (Table 3) thus supporting our hypothesis. This is a novel
finding in patients implanted with an LVAD but it is in line with the findings of previous studies that analyzed
acceptance of implantable cardioverter defibrillators (ICDs)18 and is consistent with related, small scale studies
(<34 patients) showing that in LVAD recipients distress is characterized by feelings of being useless and losing
control over one’s life6.
In addition, our regression analyses highlighted the “Return to function” and “Device-related distress”
domains of “device acceptance” as the major drivers of the correlations between device acceptance and depression/anxiety (Table 4). Importantly, the correlation remained significant even after adjusting for time since LVAD
implant and patients’ age (Table 5).
Furthermore, the patients in our cohort reported strong concerns about their body image (as assessed by the
“Body Image Concerns” subscale of the FPAS). The recorded average score in the Body Image Concern subscale
of the FPAS was in fact 39.33 ± 29.92, a value markedly higher than that of ambulatory heart failure patients
who received ICDs (10.6 ± 22.2, p < 0.01)28. Interestingly, contrary to our expectations, the regression analyses
showed no correlation between the “body image concerns” dimension of “device acceptance” and psychological
distress or QoL, when simultaneously considering the other device acceptance dimensions and relevant covariates (Tables 4 and 5). There is basically no prior data concerning body image in LVAD patients, with only two
published studies that included a total of 15 patients. Chapman et al. performed a retrospective qualitative study
on 6 LVAD recipients after transplantation or explanation and noted the feeling of being physically and psychologically scarred was a key theme characterizing the experience of LVAD recipients12. Marcucilli et al. studied 9
LVAD recipients and concluded that patients are able to develop long term psychological adaptive responses to
a number of LVAD-related consequences as they recognize the life-saving role of the device10. Our findings are
consistent with this latter notion.
Finally, the fact that recipients’ age correlated with “perceived return to function” and “device-related distress”
(Table 3) is also an important novel finding. It is consistent with our finding of a negative relation between age
and depression as measured by the PHQ-9 and a positive relation with perceived QoL as measured by KCCQ-12
QoL subscale. It is also consistent with psychological distress data recorded in stable heart failure patients living
without an LVAD and with QoL data recorded in patients implanted with an LVAD19,27. This observation suggests
that younger patients are more likely to experience emotional distress and poor QoL in the context of prolonged
circulatory support, while elderly patients might be more likely to live happily on prolonged LVAD support. This
stands to reason, as elderly patients supported with an LVAD might be more likely to achieve a functional capacity
similar to that of their peers while most young patients, despite successful mechanical circulatory support, are
likely to remain with significant functional limitations when compared with the general population in their age
range.
Limitations. The present study has several limitations. First, it is a cross-sectional study and the direction of
causality between the variables cannot be determined. Second, we assessed patient acceptance using the Florida
Patient Acceptance Survey. While this scale has been validated in patients living with heart failure, it was developed for the study of patients receiving small implantable cardiac devices and this is the first time it is used to
assess device acceptance in LVAD recipients. Third, this is a single center study and therefore most of the participants included in this study come from the same region and received LVAD-related care from the same medical
team. Fourth, we did not collect data on comorbidities. Fifth, in our study cohort, younger patients were less likely
to receive LVAD as destination therapy than their older counterparts.This finding is in line with prior work22
showing that bridge to transplantation is the most used LVAD strategy among younger patients (aged less than
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65) but it might have caused at least a portion of the increase in patient reported psychological distress noticed in
younger subject. In fact, the existing literature supports the notion that living in the continuous expectation of a
major life changing event such as organ transplant can be per se a trigger of psychological distress33–35.

Conclusions

This study shows that (1) about a quarter of real-world stable patients living with an LVAD experience clinically
relevant levels of depression or anxiety and that (2) poor device acceptance is associated with higher levels of
psychological distress. Moreover, we found that: (3) perceived return to function is a major determinant of device
acceptance; (4) body image concerns are not a major driver of device acceptance; (5) younger age correlates with
poor device acceptance and high levels of psychological distress.
Since symptoms of psychological distress have been shown to have a negative impact on self-care performance and clinical outcomes in patients with heart failure and cardiac disease36–38, our findings point at device
acceptance and perceived return to function as potential therapeutic targets to improve clinical outcomes in
LVAD recipients. Moreover, our work highlights younger LVAD recipients as a population at especially high risk
for poor patient-reported outcomes and challenges the routine implant LVADs in young patients who are not
candidates for heart transplantation.
Psychosocial interventions based on a cognitive-behavioral approach and focusing on patients’ learning of
specific coping skills have showed to be useful in managing the distress related to chronic illness39. Further studies
will be needed to test the ability of psychological interventions to promote better adjustment to LVAD implant
and improve the efficacy of this rapidly expanding therapy.
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